Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $11.68M rose 38.4% year over year, behind the +41.7% change in trailing-twelve-month research & development. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.
Context
- Research & development amounted to 11.3% of revenue in FY2025, down 1.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +38.4% toward the trailing-twelve-month pace of +41.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 33.3M USD
- Year-over-year change
- +42.4%
- 4-year CAGR
- -15.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.3M | +42.4% |
| FY2024 | 2024-12-31 | 23.38M | -4.7% |
| FY2023 | 2023-12-31 | 24.52M | -59.3% |
| FY2022 | 2022-12-31 | 60.27M | -7.6% |
| FY2021 | 2021-12-31 | 65.24M | — |
Research & Development vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's LTM Mar 2026 research & development of $36.54M is the 8th highest of the 10 companies compared; the peer median is $101.77M.
- Its year-over-year change of +41.7% is the highest of 9, against a peer median of -9.2%.
- Research & development amounts to 12.2% of revenue for RIGL, versus a peer median of 291.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $824.32M | -6.8% | -2.6% | 33.8% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $101.77M | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $66.71M | -38.5% | -7.9% | — | |
| LTM Jun 2024 | $56.93M | — | -15.5% | 877.1% | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| LTM Mar 2026 | $31.62M | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $18.13M | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding RIGL) | $101.77M | -9.2% | -2.6% | 291.9% | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Cost of Revenue | 1.08M | 1.75M | 7.11M | 18.65M | 19.62M |
| Gross Profit | 148.15M | 118.49M | 109.77M | 160.63M | 274.66M |
| Gross Margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Research & Development | 65.24M | 60.27M | 24.52M | 23.38M | 33.3M |
| Selling, General & Admin | 91.89M | 112.45M | 105.74M | 113.06M | 115.9M |
| Operating Expenses | 160.65M | 174.04M | 130.26M | 136.44M | 149.2M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| EBITDA | (11.29M) | (53.87M) | (16.98M) | 28.51M | 131.56M |
| EBITDA Margin | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
| Operating Income | (12.5M) | (55.55M) | (20.49M) | 24.19M | 125.47M |
| Operating Margin | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Interest Income | 47K | 684K | 2.27M | 2.09M | 3.68M |
| Interest Expense | 4.86M | 3.71M | 6.87M | 7.92M | 7.32M |
| Other Income / Expenses | (4.81M) | (3.02M) | (4.6M) | (5.83M) | (3.64M) |
| Income Before Tax | (17.31M) | (58.57M) | (25.09M) | 18.37M | 121.83M |
| Pre-Tax Margin | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% |
| Income Tax Expense | 605K | 0 | 0 | 881K | (245.2M) |
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Net Margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| EPS (Basic) | (1.10) | (3.40) | (1.44) | 0.99 | 20.40 |
| EPS (Diluted) | (1.10) | (3.40) | (1.44) | 0.99 | 19.48 |
| Weighted Avg Shares | 17.05M | 17.24M | 17.4M | 17.58M | 17.99M |
| Weighted Avg Shares (Diluted) | 17.05M | 17.24M | 17.4M | 17.69M | 18.84M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.